Stock Details
GSK is GSK plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 34.97$. Average daily volumn in 3 months 3.66M. Market cap 72.85B

Stock symbol : GSK. Exchange : NYSE. Currency : USD
Lastest price : 35.58$. Total volume : 2.79M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

GSK plc (GSK)
Last Price

Previous Close35.27
Day Range35.39-35.74
Bid35.58 x 1.8k
Ask35.70 x 2.9k
Average Volume3.66M
Market Cap72.85B
52 Week Range28.47-46.97
Trailing P/E13.13
Foward P/E9.03
Dividend (Yield %)4.20%
Ex-Dividend Date2023-02-23

Financial Details

According to GSK plc's financial reports the company's revenue in 2022 were 29.32B an increase( +20.83%) over the years 2021 revenue that were of 24.7B. In 2022 the company's total earnings were 14.96B while total earnings in 2021 were 4.38B( +250%).

Loading ...


GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.

Market Cap:
Total Assets:
Total Cash:

News about "GSK plc"

GSK plc (GSK) Shares Down Despite Recent Market Volatility

Source from : newsheater - 5 days ago

GSK plc (NYSE: GSK)’s stock price has decreased by -2.39 compared to its previous closing price of 35.22. However, the company has seen a gain of 0.91% in its stock price over the last five trading ...See details»

GSK plc (GSK) Stock: A Closer Look at the Analyst Ratings

Source from : newsheater - 11 days ago

GSK plc (NYSE: GSK) has a price-to-earnings ratio of 11.98x that is above its average ratio. Additionally, the 36-month beta value for GSK is 0.69. There are mixed opinions on the stock, with 9 ...See details»

Are GSK plc (NYSE: GSK) Analysts Predicting A Spike?

Source from : stocksregister - 9 days ago

GSK plc (NYSE:GSK) shares, rose in value on Thursday, March 23, with the stock price up by 1.59% to the previous day’s close as strong demand from buyers drove the stock to $35.46. Actively observing ...See details»

Client Profile: GSK plc

Source from : - 10 month ago

Filter by Former Members of Congress: All Non Former Members of Congress GSK plc $4,460,000 Elizabeth Brewer Revolving Door Profiles Non Former Members of Congress GSK plc $4,460,000 Michael Calvo No ...See details»

GSK posts higher sales and profit of $1.85 billion, lifted by specialty medicines and vaccines businesses

Source from : MarketWatch - 1 month ago

GSK PLC on Wednesday posted rising earnings and sales for the fourth quarter, which the company said were boosted by its specialty medicines and vaccines businesses. Operating profit increased to ...See details»

GSK Announces Positive Results From Phase III Trial Of Jemperli Combination In Endometrial Cancer

Source from : Business Insider - 4 days ago

GSK PLC (GSK.L, GSK) announced positive results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli ...See details»

GSK Disagrees With Ruling By California State Court - Quick Facts

Source from : Nasdaq - 8 days ago

(RTTNews) - GSK PLC (GSK.L, GSK) issued a statement as response to Sargon ruling by the California state court in respect of the Goetz case. The company noted that the scientific consensus is that ...See details»

GSK neck and neck with Pfizer in the race to get first RSV jab to market

Source from : Proactiveinvestors - 1 month ago

GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine has been endorsed by advisors to the US Food and Drug Administration (FDA), who assessed its safety and efficacy in older adults ...See details»

GlaxoSmithKline PLC

Source from : Newsweek - 22 days ago

GlaxoSmithKline plc (GSK) is a British pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's ...See details»

GSK plc (GSK) Interactive Stock Chart - Yahoo Finance

Source from : Yahoo Finance - 5 years ago

GSK plc (NYSE: GSK) and Scynexis Inc (NASDAQ: SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets). The FDA approved the antifungal for vulvovaginal ...See details»

GSK Plc: FDA Grants Approval For Jemperli For Patients With DMMR Recurrent Endometrial Cancer

Source from : Nasdaq - 1 month ago

(RTTNews) - GSK plc (GSK.L, GSK) announced the US FDA granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient recurrent or advanced ...See details»

GSK.L - | Stock Price & Latest News | Reuters

Source from : Reuters - 3 years ago

GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development.See details»

PAC Profile: GSK plc

Source from : - 1 year ago

*Based on data released by the Federal Election Commission on March 29, 2023 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...See details»

GSK loses bid to keep experts out of upcoming Zantac trial

Source from : Yahoo News - 8 days ago

(Reuters) -A California judge on Thursday denied GSK Plc's bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British ...See details»